- Clone:
- REA486 | MBM7C7
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- ICFC, MICS, IF, IHC Glossary
- Select a conjugate:
- Select a size:
Related products for BATF Antibody, anti-human, REAfinity™
Human peripheral blood mononuclear cells (PBMCs) were stimulated with CD3 and CD28 antibodies for 3 days. Cells were fixed and permeabilized using the FoxP3 Staining Buffer Set. Cells were then stained with Anti-BATF antibodies or with the corresponding REA Control (I) antibodies (left peak). Flow cytometry was performed using the MACSQuant® Analyzer. Lymphocytes were pregated for the analysis. Cell debris were excluded from the analysis based on scatter signals.
Clone REA486 recognizes the human B cell–activating transcription factor (BATF) antigen, a 14 kDa transcription factor belonging to the AP-1 family of basic leucine zipper transcription factors. BATF plays an important role in regulating differentiation and function in many lymphocyte lineages. In the CD8+ T cell lineage, increased expression of BATF in exhausted CD8+ T cells suppresses their effector function. In the CD4+ T cell lineage, BATF is required for the differentiation of interleukin 17 producing helper T cells, where it binds cooperatively with the transcription factor IRF4 and its dimerization partners c-Jun, JunB, and JunD. BATF is also important for the development of follicular helper T cells by regulating the transcription factors Bcl-6 and c-Maf. In addition, BATF is required for class-switch recombination in B cells and to regulate activation-induced cytidine deaminase as well as DNA damage checkpoint in hematopoietic stem cell self-renewal.
Additional information: Clone REA486 displays negligible binding to Fc receptors.
B-ATF1, SFA-2, SFA2, B-ATF
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Dorsey, M. J. et al. (1995) B-ATF: a novel human bZIP protein that associates with members of the AP-1 transcription factor family. Oncogene 11 (11): 2255-2265
- Kurachi, M. et al. (2014) The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells. Nat Immunol 15 (4): 373-383
- Li, P. et al. (2012) BATF-JUN is critical for IRF4-mediated transcription in T cells. Nature 490 (7421): 543-546
You have previously chosen International as your location.
What do you want to do?